ANDA 203132, held by Hospira. Cefotaxime Sodium.
As of Nov 16, 2026, ANDA 203132 (Cefotaxime Sodium), held by Hospira, was first approved by FDA on Feb 19, 2016, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 19, 2016 | Original application | Approved | None posted |
| Cefotaxime SodiumEQ 1GM BASE/VIAL · injectable;injection | Cefotaxime Sodium | Discontinued |
| Cefotaxime SodiumEQ 2GM BASE/VIAL · injectable;injection | Cefotaxime Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters